CCI Approves Abu Dhabi Investment in Indian Medical Devices Firm

The Competition Commission of India (CCI) has given approval for the acquisition of shares in Micro Life Sciences by the Abu Dhabi Investment Authority's entity, Platinum Jasmine A 2018 Trust. This includes acquiring new equity shares and a 3.06% stake from Bilakhia Holdings Pvt Ltd. Micro Life Sciences is a major player in medical device manufacturing in India.

The Competition Commission of India (CCI) has approved a strategic investment by the Abu Dhabi Investment Authority's entity, Platinum Jasmine A 2018 Trust, into Indian company Micro Life Sciences. This deal involves purchasing new equity shares and acquiring a 3.06% existing stake from Bilakhia Holdings Pvt Ltd.

The CCI's approval, announced on Tuesday, involves the acquisition of shares in a prominent Indian firm specializing in medical device manufacturing. This investment is expected to bolster Micro Life Sciences' position in the healthcare sector.

The move signifies continued international interest in India's medical device industry, highlighting the sector's growth potential and the attractiveness of Indian businesses to global investors.

(With inputs from agencies.)